Welcome to our dedicated page for Janux Therapeutics news (Ticker: JANX), a resource for investors and traders seeking the latest updates and insights on Janux Therapeutics stock.
Janux Therapeutics, Inc. (NASDAQ: JANX) is a clinical-stage biopharmaceutical pioneer developing tumor-activated immunotherapies through its proprietary TRACTr and TRACIr platforms. This page serves as the definitive source for verified company announcements, offering stakeholders timely access to essential updates.
Key resources include: Press releases detailing clinical trial progress, regulatory milestones for novel cancer therapies, strategic partnerships in biopharmaceutical development, and financial disclosures. Our curated collection helps investors track innovations in bispecific T cell engagers and tumor microenvironment targeting.
Bookmark this page to monitor Janux's advancements in addressing immunotherapy challenges like systemic toxicity and tumor specificity. All content is sourced directly from official company communications, ensuring reliability for research and analysis needs.
Janux Therapeutics (JANX) has presented promising preclinical data for its lead tumor-targeting therapies, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008), at the PEGS Boston Conference. Both candidates demonstrate enhanced safety and pharmacokinetics (PK) profiles with minimal healthy tissue toxicity, evidenced by studies in non-human primates. Janux is on track for IND filings with the FDA, aiming for JANX007 in 1H 2022 and JANX008 in 2H 2022, aiming to improve treatment outcomes for various cancers including metastatic prostate and colorectal cancers.
Janux Therapeutics (Nasdaq: JANX) reported financial results for Q4 and the full year ending December 31, 2021. The company's cash resources surged to $375.0 million from $7.8 million a year earlier, aiding ongoing development of its immunotherapy pipeline. Notably, Janux nominated its first TRACIr candidate for solid tumors and remains on track for IND submissions for two TRACTr candidates in 2022. However, it reported a net loss of $32.7 million for the year, up from $6.8 million in 2020, indicating increased expenditures related to R&D and operational activities.
Janux Therapeutics, Inc. (NASDAQ: JANX) announced its participation in three upcoming investor conferences. These include Cowen's 42nd Annual Health Care Conference on March 7, Barclays Global Healthcare Conference on March 16, and Oppenheimer's 32nd Annual Healthcare Conference on March 17. Janux focuses on developing innovative immunotherapies using its proprietary TRACTr and TRACIr platforms. The company aims to address challenges in treating solid tumors with its lead product candidates targeting PSMA, EGFR, and TROP2, currently in various stages of development.
Janux Therapeutics (NASDAQ: JANX) has appointed Dr. Byron Robinson as Chief Strategy Officer. With 30 years of experience in the pharmaceutical industry, including leadership roles at Merck KGaA and Bayer, Dr. Robinson is expected to enhance Janux's clinical strategy and execution. His key contributions include overseeing late-stage development of oncology assets. Dr. Robinson's expertise will be pivotal as Janux advances its TRACTr and TRACIr platforms in developing innovative cancer immunotherapies.
Janux Therapeutics (NASDAQ: JANX) announced its participation in a virtual fireside chat at the H.C. Wainwright BioConnect Conference from January 10 to 13. The chat will be available for on-demand viewing starting January 10 at 7:00 a.m. ET on Janux's website. The company focuses on developing innovative immunotherapies using its TRACTr and TRACIr platforms, aimed at improving treatment for cancer patients. Key areas of development include T cell engagers targeting PSMA, EGFR, TROP2, and PD-L1xCD28, all in the IND-enabling or discovery stage.
Janux Therapeutics (Nasdaq: JANX) reported its third-quarter financials for 2021, showcasing a significant increase in cash reserves, totaling $387.5 million compared to $7.8 million as of December 2020. The company continues to advance its immunotherapy pipeline, with two IND filings planned for 2022 for the PSMA-TRACTr and EGFR-TRACTr candidates. However, Janux reported a net loss of $10.8 million this quarter, up from $1.3 million in the same period last year, influenced by increased R&D and operational costs.
Janux Therapeutics (NASDAQ: JANX) will participate in two virtual investor conferences. The first is Cowen’s 5th Annual IO Next Summit on November 15, 2021, from 12:15-12:35 p.m. ET. The second is the Evercore ISI 4th Annual Health CONx Conference on December 2, 2021, from 2:40-3:00 p.m. ET. Archived replays of both sessions will be available for about 90 days on Janux's website. Janux is focused on developing innovative immunotherapies using its TRACTr and TRACIr platforms to treat cancer, with products targeting various cancer-specific antigens.
Janux Therapeutics, Inc. (NASDAQ: JANX) announces the appointment of Ronald W. Barrett, Ph.D. and Alana McNulty to its Board of Directors. Dr. Barrett brings over 30 years of biopharmaceutical experience, having advanced multiple drug candidates to FDA approval. Ms. McNulty, with her extensive finance background, has managed transactions exceeding $2 billion. CEO David Campbell emphasizes their complementary expertise as vital for advancing Janux's cancer treatment programs. Janux focuses on innovative immunotherapies using its TRACTr and TRACIr platforms to treat solid tumors and is currently advancing several drug candidates.
Janux Therapeutics, Inc. (NASDAQ: JANX) announced its participation in the virtual H.C. Wainwright 23rd Annual Global Investor Conference from September 13-15, 2021. The corporate presentation will be accessible for on-demand viewing starting September 13 at 7:00 a.m. ET through Janux's website. Janux specializes in developing novel immunotherapies, focusing on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) technologies. Their lead programs target key cancer markers and aim to improve treatment efficacy for solid tumors.
Janux Therapeutics (Nasdaq: JANX) has appointed Dr. Shahram Salek-Ardakani as Chief Scientific Officer. Dr. Salek-Ardakani, with over 20 years in drug development, will spearhead the advancement of Janux's Tumor Activated T Cell Engager (TRACTr) platform technology. His expertise includes formulating innovative T-cell-targeted therapies at Pfizer. This leadership change aims to enhance Janux's pipeline of T cell engager immunotherapies designed to improve cancer treatment while minimizing toxicity. The TRACTr platform targets specific tumor markers to optimize efficacy and safety.
FAQ
What is the current stock price of Janux Therapeutics (JANX)?
What is the market cap of Janux Therapeutics (JANX)?
